Sponsored Whitepaper: Why deep freeze is the way to go when storing high-quality biopharmaceuticals
Why deep freeze?
The storage of high-quality biopharmaceuticals is a major challenge for the industry. Proteins are easily affected by changes in ambient conditions and react sensitively to changes in their environment. The complex three-dimensional protein structure is held together by weak, intra-molecular interactions and is therefore particularly delicate. The native folding of protein substances is essential for their efficacy: only if a protein is correctly folded will the right molecules be bound. Changes in the structure will have fatal consequences; in certain cases, they do not only result in a loss of efficacy, but may even cause pathological effects.
This means the process of storing an active protein substance must be the result of an exceptionally careful and sophisticated design process and all influencing factors must be known since the substance will often need to be stored for years.
The pharmaceutical industry has found deep-freezing to be a stable method of storing protein solutions. The active ingredient is cooled in freezing chambers or in controlled freezing containers until the whole bulk solution has reached the required temperature level. However, we know from practice that rearrangements and structural effects will occur in proteins even in the frozen state, which can also result in changes to their native structure. Damaging alterations may, for example, lead to increased aggregate formation or flocculation. In order to preserve the product quality, freezing at very low temperatures is required. A change in the protein structure is to be prevented by choosing temperatures below the glass transition temperature.
The change in product quality and the various freezing effects depend on the one hand on the process parameters selected, and on the other hand they are strongly influenced by the composition of the protein solution. In most cases, quality changes caused by the effects described above will entail additional process steps and drug losses. Product loss must in any case be reduced to a minimum. Identifying the relationships between the composition of the protein solution, concentration, pH value, additives, cryo-protectors or additives and the behaviour of the quality of the protein solution after one or more freeze and thaw cycles is the basis for advanced understanding of the F&T process.
More risk management, less product loss
The frozen protein solution becomes increasingly concentrated as ice crystals form during freezing. The auxiliary substances, such as buffer salts, gradually lose their effect depending on their solubility. The pH value of a sodium phosphate buffer can, for example, drop from 7.0 to below 4.0 during freezing. The ionic strength can also increase significantly. In addition to that, the formation of ice crystals leads to an ice-liquid interface which can impact protein folding. The influencing parameters and their effects differ widely for each substance. This is why they are examined for each product individually in the lab, using tailor-made F&T equipment. The aim is to understand the product behaviour in one freeze and thaw cycle in order to be able to derive optimum process understanding from this knowledge.
Once the basic behaviour of the protein solution during freezing has been understood, the F&T processes developed in the lab will be scaled to pilot scale. The freezing process is analysed, optimised further and precisely defined. The specified process is the basis for industrial processing and thus an important element in the development of optimum storage of the protein substance.
The pilot scale allows for various analytical methods and represents a valuable intermediary scale. The most suitable process parameters for the product need to be determined and optimised. Contrary to initial, business driven assumptions this does not necessarily have to be the speed of freezing, because one thing is for sure in the F&T process: quality takes precedence over efficiency. As explained above, the PilotFreeze examines the processes that were previously developed in the laboratory to prepare them on a larger scale for industrial processing. Practical applications have shown that the PilotFreeze can also be used to verify existing industrial F&T processes. The processes are then checked again and optimised in the course of optimisation or retrospective process validation before they are fed back to industrial production by means of a technology transfer. In summary we can say the PilotFreeze analysis is as important for the process development of new protein solutions as it is for the optimisation of current processes.
Does deep-freezing guarantee optimum product quality?
Only at temperatures below the glass transition temperature can it be assumed that there will be no more movements and structural changes in the structure of the proteins in solution. Consequently, a temperature of below -70°C was defined as a prerequisite for the freezing system for particularly sensitive products.
While freezing containers on an industrial scale of up to 500 l are already established practice for an industrial freezing process in the moderate temperature range, the large-scale solution for freezing highly sensitive and active pharmaceutical proteins in a low temperature range of <-70°C needed a new development. The first 200 l freezing container for freezing down to -85°C emerged in a cooperation project, which was yet another result from the many years of cooperation between ZETA and Boehringer Ingelheim in the field of freezing processes.
In a series of tests with the proven ZETA PilotFreeze, the freeze and thaw processes were investigated and the effects on product quality in the form of aggregation, fragment formation, turbidity or particle formation were analysed. The efficiency of the process was the prime objective of designing the vessel geometry. Important parameters for this were the consideration of product throughput, achievable temperatures, the geometric conditions in the tank and the ice layer thicknesses achieved. Calculations for achievable cooling and thawing rates were carried out and later verified by means of experiments.
The development of the new vessel included some major challenges for the ZETA engineering team; they had to find materials suited for the low temperature range that would allow a stable and safe freezing process and withstand long storage time. Another important criterion for the right choice of material was personal safety. T
his special requirement is owed to the product itself, which as a highly active drug calls for special precautions in worker protection.
Theoretical calculations on freezing rates were empirically confirmed in the test series. These results enabled BI to develop a concrete calculation model, which is the central element of a scientific publication commissioned by BI.
Together with the freezing systems, which serve the different process volumes, ZETA covers the entire development process of a freezing unit – from the product investigations to the freezing plant on an industrial scale. Professional project teams take the current stage of every project product into account. In this way, the mutual knowledge gain can be maximised through cooperation, the product quality can be maintained in the best possible way and the time to implement processes and set up plants can be accelerated in an optimum manner.
About ZETA:
With a staff of more than 500 people and its headquarters in Lieboch/Austria and nine subsidiaries in Europe, the ZETA Group is one of the biggest suppliers of engineering, automation and process technology for biopharmaceutical applications.
The product range includes high-tech equipment, pilot plants and turnkey industrial plants for the biotechnological production of pharmaceutical substances. ZETA is your expert in the development of customised process solutions along the entire development and production process for aseptic applications, from laboratory to industrial scale.
The ZETA facility in Lebring, Southern Styria, develops and builds products that support ZETA customers along the process of producing pharmaceutical agents. ZETA is specialised in the development, enhancement and improvement of mixing technologies and freeze & thaw systems. The solution experts of the ZETA R&D department develop innovative products and patent them together with their customers and in cooperation with research centres and universities.